NIFTY NINE IN NINETY NINE PLUS ONE Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : NIFTY NINE IN NINETY NINE PLUS ONE

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike McFarland who wrote (226)	1/24/1999 11:31:00 PM
From: Steve Lokness	Read Replies (2) of 613

Mike; Since I'm the other that has GLGC, I will had my understanding to your questions. GLGC does have a considerable tissue bank which was part of (maybe more than part of) the reason that they bought ONM. Man, the brain is going as I can't remember the name of the company, but believe the listing letters were ONM. I think it was a great buy by GLGC, but there are others that wondered about it GLGC has their own patented "flow through chips" and also uses AFFX chip technology, depending I suppose on what use is intended. They have an agreement with AFFX. GLGC believes that their method of identifying the progression of disease and understanding this progression will speed the development of drugs. It is a little hard to explain and you would do well to get the investor information on this one. I do believe that this is incredible science - will GLGC be the winner here is a lot harder one to answer. Steve A question for you: who are you looking at in the genomic/bioinformatic area and why?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next